Revisiting retinoic acid in AML therapy: mechanisms of action and rational combination strategies.
Review proposes retinoic acid combinations for common leukaemia types beyond its established use, suggesting near-term clinical trial opportunities.
Ozcan et al. review molecular mechanisms of retinoic acid action in AML, arguing that ATRA's differentiation-inducing properties extend beyond APL to other AML subtypes when combined with appropriately selected targeted agents. The review proposes rational combination strategies with venetoclax, hypomethylating agents, and IDH inhibitors based on synergistic mechanistic rationale and emerging preclinical data, with implications for near-term clinical trial design in non-APL AML.
What the study was
- Study design
- Narrative review
- Population
- AML patients (non-APL subtypes)
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Br J Cancer
Why it surfaced
British Journal of Cancer review repositioning retinoic acid for broader AML therapy; near-term combinatorial trial implications.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.